Sign In
Buy TRS
TriMas Earnings Calls
| Release date | Apr 30, 2026 |
| EPS estimate | $0.190 |
| EPS actual | $0.240 |
| EPS Surprise | 26.65% |
| Revenue estimate | 158.243M |
| Revenue actual | 168.28M |
| Revenue Surprise | 6.34% |
| Release date | Feb 26, 2026 |
| EPS estimate | $0.410 |
| EPS actual | $0.400 |
| EPS Surprise | -2.44% |
| Revenue estimate | 192.956M |
| Revenue actual | 155.49M |
| Revenue Surprise | -19.42% |
| Release date | Oct 28, 2025 |
| EPS estimate | $0.564 |
| EPS actual | $0.610 |
| EPS Surprise | 8.16% |
| Revenue estimate | 262.054M |
| Revenue actual | 269.26M |
| Revenue Surprise | 2.75% |
| Release date | Jul 29, 2025 |
| EPS estimate | $0.500 |
| EPS actual | $0.610 |
| EPS Surprise | 22.00% |
| Revenue estimate | 262.054M |
| Revenue actual | 274.76M |
| Revenue Surprise | 4.85% |
Last 4 Quarters for TriMas
Below you can see how TRS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 29, 2025 |
| Price on release | $34.87 |
| EPS estimate | $0.500 |
| EPS actual | $0.610 |
| EPS surprise | 22.00% |
| Date | Price |
|---|---|
| Jul 23, 2025 | $31.55 |
| Jul 24, 2025 | $31.53 |
| Jul 25, 2025 | $31.43 |
| Jul 28, 2025 | $31.48 |
| Jul 29, 2025 | $34.87 |
| Jul 30, 2025 | $35.70 |
| Jul 31, 2025 | $35.73 |
| Aug 01, 2025 | $34.92 |
| Aug 04, 2025 | $35.04 |
| 4 days before | 10.52% |
| 4 days after | 0.488% |
| On release day | 2.38% |
| Change in period | 11.06% |
| Release date | Oct 28, 2025 |
| Price on release | $37.89 |
| EPS estimate | $0.564 |
| EPS actual | $0.610 |
| EPS surprise | 8.16% |
| Date | Price |
|---|---|
| Oct 22, 2025 | $38.36 |
| Oct 23, 2025 | $39.45 |
| Oct 24, 2025 | $39.95 |
| Oct 27, 2025 | $39.07 |
| Oct 28, 2025 | $37.89 |
| Oct 29, 2025 | $37.02 |
| Oct 30, 2025 | $35.83 |
| Oct 31, 2025 | $35.53 |
| Nov 03, 2025 | $36.12 |
| 4 days before | -1.23% |
| 4 days after | -4.67% |
| On release day | -2.30% |
| Change in period | -5.84% |
| Release date | Feb 26, 2026 |
| Price on release | $38.00 |
| EPS estimate | $0.410 |
| EPS actual | $0.400 |
| EPS surprise | -2.44% |
| Date | Price |
|---|---|
| Feb 20, 2026 | $37.08 |
| Feb 23, 2026 | $36.51 |
| Feb 24, 2026 | $36.40 |
| Feb 25, 2026 | $36.85 |
| Feb 26, 2026 | $38.00 |
| Feb 27, 2026 | $39.08 |
| Mar 02, 2026 | $37.94 |
| Mar 03, 2026 | $38.33 |
| Mar 04, 2026 | $39.52 |
| 4 days before | 2.48% |
| 4 days after | 4.00% |
| On release day | 2.84% |
| Change in period | 6.58% |
| Release date | Apr 30, 2026 |
| Price on release | $37.02 |
| EPS estimate | $0.190 |
| EPS actual | $0.240 |
| EPS surprise | 26.65% |
| Date | Price |
|---|---|
| Apr 24, 2026 | $36.92 |
| Apr 27, 2026 | $37.58 |
| Apr 28, 2026 | $36.78 |
| Apr 29, 2026 | $36.08 |
| Apr 30, 2026 | $37.02 |
| May 01, 2026 | $38.53 |
| May 04, 2026 | $39.11 |
| May 05, 2026 | $41.46 |
| May 06, 2026 | $41.61 |
| 4 days before | 0.271% |
| 4 days after | 12.40% |
| On release day | 4.08% |
| Change in period | 12.70% |
TriMas Earnings Call Transcript Summary of Q1 2026
TriMas reported a strong start to 2026 following the March 16 divestiture of TriMas Aerospace. Q1 net sales rose >10% to $168M driven by 7.3% organic growth and favorable FX; operating margins expanded 120 bps; adjusted EPS was $0.24 (up 60% YoY). The Aerospace sale generated roughly $1.2–1.4B of gross proceeds, leaving the company with about $913M net cash at quarter-end; management has used a portion to repurchase ~4.5M shares and is holding the remainder in interest-bearing accounts (earning ~3.5%). Management reaffirmed full-year 2026 guidance: revenue growth of 3%–6%, operating margins improving into the 14%–15% range (300+ bps improvement vs. 2025), and adjusted diluted EPS $1.50–$1.70 (reflecting significant benefit from invested proceeds and cost reductions). Operationally, TriMas expects $10M of cost savings in 2026 (>$15M run-rate thereafter), is consolidating a Packaging facility (Atkins, AR) to realize additional savings, and plans to focus capital deployment on organic growth and targeted acquisitions in packaging and life sciences. Management flagged ongoing monitoring of geopolitical risks and potential commodity pass-through timing lags but expects sequential margin improvement through Q2 and Q3 as cost actions and commodity recovery take effect.
